Specialty Pharmacy

Screening of newborn children for hepatitis C and new, more effective hepatitis C treatments may virtually eliminate the disease in the United States by 2036.

Clinical hold on Tekmira's Ebola treatment changed to partial hold by the FDA.

In a study that has the potential to change public health recommendations for breast cancer screening, researchers have validated the value of mammography in older women.

More than 90% of women in the program received timely follow-up care.

The World Health Organization will examine an unproven Ebola treatment that showed promise in 2 Americans infected with the virus.

Patients who told their employer about a multiple sclerosis diagnosis tended to have better odds of remaining employed and had a longer tenure than those who did not.

Efforts to halt the spread of Ebola continue as a Saudi Arabian man suspected of having the virus adds to the climbing death toll in West Africa.

Increasingly, sharing of information online through social media has made blinding of placebo groups in clinical trials virtually impossible. In some disease states, particularly multiple sclerosis, virtual placebo groups may offer a solution.

FDA will no longer require Genzyme to continue the Risk Evaluation and Mitigation Strategy program.

A New York man who showed symptoms of Ebola has been deemed unlikely to have the virus.

Researchers in Taiwan have found an increased risk for head and neck cancers among patients with diabetes mellitus.

Treatment with dimethyl fumarate improved or stabilized health-related quality of life scores in patients with relapse-remitting multiple sclerosis compared to placebo.

Financial hurdles delay biopharmaceutical companies from developing treatment amidst largest Ebola hemorrhagic fever outbreak in history.

QS/1 pharmacies already have access to new Signature Indicator to validate electronic prescriptions for controlled substances.

Male latex condoms are still the best strategy for reducing the spread of HIV infection.

Armada Health Care Chief Strategy Officer Thomas Cohn discusses details of the NASP and SPAARx merger and how the unified organization will help guide specialty pharmacy into the future.

The 11th annual event is scheduled to begin May 5, 2015 at the Wynn Conference Center in Las Vegas.

Patients who responded to brodalumab showed improvement in skin condition and joint swelling.

Delegates meet to discuss emerging trends in specialty pharmacy.

Recommendations for co-morbidities identified as an important step for the optimal care of patients.

Studies show impressive response rates in patients given Zydelig (idelalisib) for treatment of three types of blood cancer.

NASP/SPAARx merger creates one, unified voice representing the fastest growing segments in the pharmacy and health care industries.

Biologics License Application filed for filgrastim by Sandoz.

Temple University researchers' tool requires further investigation, targets virus cells specifically.

Launch of premium-priced agents powering growth forecast.

Blood test three times more specific in detection of prostate cancer than prostate-specific antigen.

Bill Barre, RPh, vice president of business development at MedImpact Healthcare Systems, discusses key trends in pharmacy benefit management that specialty pharmacies need to be aware of.

Overall annual diagnosis rate dropped 30% from 2002 to 2011, while a significant increase was found among young men who have sex with men.

CEO of Avella Specialty Pharmacy Rebecca M. Shanahan, Esq., discusses how accountable care organizations will impact future trends in specialty pharmacy.